|
Novel Abiraterone Conjugate with lower liver toxicity and high oral bioavailability
|
Oncology/Cancer
|
Prostate cancer
|
PCC
|
Global
| |
|
Best-in-class BCL-XL PROTAC
|
Ophthalmology disease
|
Ocular fundus pathology,DME,DR
|
PCC
|
Global
| |
|
Best-in-class RIPK2 PROTAC: a Novel therapeutic approach for Inflammatory bowel disease
|
Immunological disease
|
Inflammatory bowel disease
|
PCC
|
Global
| |
|
First-in-class (FIC) ER stress modulator
|
Oncology/Cancer
|
NSCLC,Pancreatic Cancer,Ovarian Cancer,Cervical Cancer,Liver Cancer,Skin Cancer
|
PCC
|
Global
| |
|
GPCR selective agonist
|
Immunological disease
|
Duchenne muscular dystrophy,Systemic lupus erythematous;,Ulcerative colitis;,Ankylosing spondylitis
|
PCC
|
Global
| |
|
Highly potent and selective 2nd-gen RET inhibitor against wild-type and broad-acquired drug-resistant mutant cancers
|
Oncology/Cancer
|
Thyroid cancer,Non-small-cell lung cancer(NSCLC)
|
PCC
|
Global
| |
|
Novel selective inhibitor for Autoimmune disease therapy
|
Immunological disease
|
Rheumatoid Arthritis,Systemic Lupus Erythematosus, Lupus Nephritis
|
PCC
|
Global
| |
|
See in our "Antibody Licensing" platform
|
|
Next to "Licensing" Tab in the top
|
PCC
|
| |
|
Selective POLQ inhibitor
|
Oncology/Cancer
|
Pancreatic cancer,BRCAm ,other DDR-deficient tumors
|
PCC
|
Global
| |
|
siRNA drug targeting Inhibin beta E (INHBE)
|
Immunological disease
|
Obesity
|
PCC
|
Global
| |
|
Anti-TF nanobody ADC
|
Oncology/Cancer
|
Pancreatic cancer,NSCLC,TNBC,Brain metastasis of tumors
|
Preclinical
|
Global
| |
|
CCR8 mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
|
FRa BsAb (sequence cooperation)
|
Oncology/Cancer
|
Ovarian cancer
|
Preclinical
|
Global
| |
|
GCC mAb (sequence cooperation)
|
Oncology/Cancer
|
Solid Tumor
|
Preclinical
|
Global
| |
|
Novel target small molecule inhibitor
|
Cardiovascular
|
Myocardial ischemia-reperfusion injury, Heart failure with atherosclerosis
|
Preclinical
|
Global
| |
